ReviewTrends in immunology2012
CD22 and Siglec-G in B cell function and tolerance.
Review in Trends in immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 66 citations in OpenAlex.
- Molecular Characterization and Expression Analysis ofBiology · 2026Article
- Considering the immunogenicity of PEG: strategies for overcoming issues with PEGylated nanomedicines.Nanomedicine (London, England) · 2025Review
- Biomaterial engineering strategies for B cell immunity modulations.Biomaterials science · 2024Review
- Article
- Activation of immune signals during organ transplantation.Signal transduction and targeted therapy · 2023Review
- Core Fucosylation Regulates the Function of Pre-BCR, BCR and IgG in Humoral Immunity.Frontiers in immunology · 2022Review
- Extracellular CIRP decreases Siglec-G expression on B-1a cells skewing them towards a pro-inflammatory phenotype in sepsis.Molecular medicine (Cambridge, Mass.) · 2021Article
- Therapeutic Potential of B-1a Cells in COVID-19.Shock (Augusta, Ga.) · 2020Review
- Review
- RNA-binding protein Ptbp1 is essential for BCR-mediated antibody production.International immunology · 2019Article
- Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma.Biomarker research · 2019Review
- CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- CD11c+ T-bet+ memory B cells: Immune maintenance during chronic infection and inflammation?Cellular immunology · 2017Review
- CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells.Journal of the American Chemical Society · 2017Article
- Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.Blood advances · 2017Article
- From Immunologically Archaic to Neoteric Glycovaccines.Vaccines · 2017Review
- Reconstituted B cell receptor signaling reveals carbohydrate-dependent mode of activation.Scientific reports · 2016Article
- CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.Integrative biology : quantitative biosciences from nano to macro · 2015Article
- α2,6-linked sialic acids on N-glycans modulate the adhesion of hepatocarcinoma cells to lymph nodes.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Siglecs induce tolerance to cell surface antigens by BIM-dependent deletion of the antigen-reactive B cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The immune system has evolved into two main arms: the primitive innate arm that is the first line of defense but relatively short-lived and broad acting; and the advanced adaptive arm that generates immunological memory, allowing rapid, specific recall responses. T cell-independent type-2 (TI-2) antigens (Ags) invoke innate immune responses. However, due to its 'at the ready' nature, how the innate arm of the immune system maintains tolerance to potentially abundant host TI-2 Ags remains elusive. Therefore, it is important to define the mechanisms that establish innate immune tolerance. This review highlights recent insights into B cell tolerance to theoretical self TI-2 Ags, and examines how the B cell-restricted sialic acid binding Ig-like lectins (Siglecs), CD22 and Siglec-G, might contribute to this process.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.